NVMDF - NVMDF STOCK NEWS

Novamind Inc. (CSE:NM)(OTCQB:NVMDF) has launched a groundbreaking Psychedelic Palliative Care Program at its Murray, Utah clinic. This innovative program combines psychedelic medicine with psychotherapy to support patients facing chronic and serious illnesses.

Led by Dr. Paul Thielking, the initiative aims to alleviate symptoms of depression, particularly in patients where traditional treatments have failed. The program will investigate the use of ketamine and explore psilocybin through clinical research, building on studies from notable institutions. This effort addresses a gap in the healthcare system for emotional and psychological support during serious illness.

Novamind (OTCQB:NVMDF) will participate in the PSYCH Investor Summit on October 7, 2021, where Chief Medical Officer Dr. Reid Robison will deliver a keynote address on the evolving landscape of mental health and psychedelic medicine. The keynote will discuss the challenges and opportunities in ketamine-assisted psychotherapy and the operational model that increases access to these therapies. Dr. Robison will also join an expert panel focusing on technology's role in psychedelic-assisted therapy. The company is featured in the latest edition of the Psychedelics as Medicine Report.

Novamind Inc. has announced the opening of its sixth integrative psychiatry clinic in Murray, Utah, which also serves as its third clinical research site. The company is poised to facilitate 65,000 patient visits this year, enhancing its capacity to conduct extensive clinical trials for psychedelic medicine. CEO Yaron Conforti emphasized the significance of this expansion in scaling effective psychedelic therapies. Two more clinics in Utah are expected to open by the end of 2021, with the Salt Lake City location launching in October and Park City in November.

Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) announced its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC) in the U.S. This eligibility facilitates faster stock and cash transactions, benefiting investors by accelerating settlement processes. CEO Yaron Conforti emphasized that this step enhances liquidity and bolsters Novamind's presence in the U.S. capital markets. The company focuses on psychedelic medicine, offering treatments through its network of clinics and clinical research sites.

Novamind Inc. (OTCQB:NVMDF) is set to participate in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021, where CEO Yaron Conforti will be part of a panel discussing the disruptive potential of psychedelic medicine in mental healthcare.

On September 30 at 12:35 PM EST, Conforti will address the topic, followed by an update on the Company's expanding network of psychiatry clinics focused on psychedelic treatments. A Q&A session will conclude the presentation. Register for the event at benzinga.com.

Novamind Inc. has been included in the AdvisorShares Psychedelics ETF (PSIL), the first U.S.-listed ETF focused on the psychedelics sector. The ETF aims for long-term capital appreciation by investing in leading companies in this emerging industry. Novamind's CEO, Yaron Conforti, highlighted this achievement as a significant recognition of the company's growth in the psychedelics space, where it operates clinics and research sites for ketamine-assisted therapy and other treatments.

Novamind Inc. (CSE:NM)(OTCQB:NVMDF) announced its participation in the Life Sciences Investor Forum on September 16, 2021, at 12:00 PM EST. Dr. Reid Robison, the Chief Medical Officer, will present Novamind's plan for expanding access to psychedelic medicine across the U.S. through its clinics and research sites. An open Q&A session will follow the presentation, and a recorded webcast will be available for those unable to attend live. Novamind focuses on mental health with services such as ketamine-assisted psychotherapy.

Novamind (CSE:NM)(OTCQB:NVMDF) announced that its subsidiary, Cedar Clinical Research, will host a phase III trial for KarXT, an investigational therapy for schizophrenia. This study, titled "EMERGENT-5," aims to assess the long-term safety and efficacy of KarXT in addressing the unmet needs of approximately 20 million individuals affected by schizophrenia. With 65,000 anticipated clinic visits in 2021, CCR demonstrates significant growth, supporting its role in innovative mental health treatments.

Novamind Inc. (CSE:NM)(OTCQB:NVMDF) has successfully listed its common shares on the OTCQB Venture Market as of September 9, 2021. This approval marks a significant milestone for the company, enhancing its ability to reach a wider audience and attract both institutional and retail investors. Novamind is focused on expanding access to psychedelic-assisted psychotherapy through its network of clinics and clinical research sites. The company also continues trading on the Canadian Securities Exchange and Frankfurt Stock Exchange under existing symbols.